MYL6B, a myosin light chain, promotes MDM2-mediated p53 degradation and drives HCC development
Xingwang Xie(Peking University), Hongsong Chen(Inner Mongolia University for Nationalities), Xueyan Wang(Shenzhen Institute for Drug Control), Qian Chen(Suzhou Research Institute), Yu Wang(ChemoCentryx (United States)), Cong Xu(Tongji Hospital), Nan Wu(Propulsion Science and Technology (United States)), Lai Wei(Nanjing University of Finance and Economics), Ran Fei(Peking University), Weijia Liao(Guilin Medical University)
Cited by 26
Related Papers
Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
|Nature Communications|2016|1.6k
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development
|The Journal of Experimental Medicine|2006|1.3k
Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery
|Nature Communications|2022|632
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
|Trends in Pharmacological Sciences|2020|304
New progress in the pharmacology of protocatechuic acid: A compound ingested in daily foods and herbs frequently and heavily
|Pharmacological Research|2020|301